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Abstract
Acute ischemic cardiogenic shock is associated with poor prognosis, and the
impact of inotropic support on diastolic function in this context is unclear.
We assessed two suggested new inotropic strategies in a clinically relevant
pig model of ischemic acute heart failure (AHF): treatment with the myosin
activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I).
Left ventricular (LV) ischemia was induced in anesthetized pigs by coronary
microembolization (n = 12). The animals then received OM (bolus 0.75 mg/
kg, followed by 0.5 mg/kg per h) (n = 6) or D+I (5 lg/kg per min +
0.29  0.16 mg/kg) (n = 6), respectively. Ischemia reduced the stroke vol-
ume (SV), despite the increased left atrial pressure associated with impaired
LV early relaxation, systolic dilatation, and LV late diastolic stiffness. Both
treatments improved systolic ejection, but only D+I increased the SV from
26  5 to 33  5 mL. D+I enhanced LV early relaxation (Tau; from
45  11 to 29  4 msec) and prolonged the diastolic time (DT) from
338  60 to 352  40 msec. In contrast, OM prolonged Tau (42  5 to
62  10 msec) and shortened the DT (from 326  68 to 248  84 msec).
Our data suggest that enhanced early relaxation by D+I improves LV pump
function in postischemic acute heart failure. In contrast, OM worsened lusi-
tropy in this model.
Introduction
Left ventricular (LV) acute heart failure (AHF) following
myocardial infarction is a serious and life-threatening
situation requiring urgent treatment (Hochman et al.
1999). Medical support with dobutamine is indicated for
persistent compromised organ perfusion following revas-
cularization (Ponikowski et al. 2016). A primary focus
of this treatment is the restoration of contractility by
improving systolic function and ventricular unloading.
Little attention has been paid to understanding the dias-
tolic pathophysiology in these patients. This is relevant
because many patients experience tachycardia mediated
by hypotensive baroreflex activation and the administra-
tion of b-adrenergic drugs. However, tachycardia is only
beneficial when it results in a significant increase in car-
diac output (CO). Shortening of diastole requires an
enhanced filling rate to maintain stroke volume (SV).
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During physiological tachycardia (i.e., exercise), the fill-
ing rate is increased as the ventricle pulls blood from
the atrium, that is “diastolic suction”. The suction forces
are generated during the preceding systole when the
myocardium is compressed below the resting equilibrium
shape. This compression generates diastolic restoring
forces when the ventricle recoils and regains its passive
shape and subsequently actively draws blood into the
cavity (Opdahl et al. 2009). Suction is thought to be
severely impaired during acute ischemia due to weak-
ened contractility and an elevated end-systolic volume
(ESV). Thus, ventricular unloading during systole with
inotrope treatment may benefit both diastolic and sys-
tolic myocardial function. A caveat to using classic ino-
tropes is their inherent tachycardic effect exerted via the
b-1 receptor. In an ischemic heart with diastolic dys-
function, this effect may cause decompensation due to a
discrepancy between the required filling time and the
heart rate (HR). Thus, a treatment principle that selec-
tively restores impaired contractility with a limited
chronotropic response would be theoretically advanta-
geous.
A selective HR-reducing agent, ivabradine, has pro-
vided an opportunity to test a rate-controlled treatment
paradigm. Recent studies have demonstrated that the
combined use of dobutamine and ivabradine (D+I) to
treat AHF is well tolerated in patients (Cavusoglu et al.
2015) and energetically neutral for the heart (Bakkehaug
et al. 2016). D+I has also been tested in the treatment
of patients in cardiogenic shock (CS) (Gallet et al.
2014).
An alternative AHF treatment is a novel inotrope,
omecamtiv mecarbil (OM). This drug has recently been
evaluated in a phase 2 trial for the treatment of patients
with AHF (Teerlink et al. 2016). OM is classified as a
myosin activator, and it has been suggested to function
independently of calcium currents by increasing the
number of myosin heads interacting with actin filaments.
This mechanism has been described as “more hands pull-
ing on the rope” (Teerlink et al. 2011). OM extends the
systolic ejection time (SET) and increases systolic unload-
ing (reducing “end-systolic” volume), thereby increasing
the LV ejection fraction (EF). However, such an impact
on the cardiac cycle might hamper diastolic function and
result in an insufficient filling time, particularly during
tachycardia.
In this study, we performed a comprehensive invasive
assessment of diastolic function in a pig model of sev-
ere LV ischemia. The aim was to assess the therapeutic
potential of omecamtiv mecarbil and dobutamine




The experimental protocol was approved by the local
steering committee of the National Animal Research
Authority at the Faculty of Health Sciences, UiT The Arc-
tic University of Norway. Castrated male domestic pigs
(32.4  2.2 kg) were adapted to the new environment for
5–7 days. The animals were fasted overnight and were
provided water ad libitum prior to the experiments.
Anesthesia and surgical preparation
The pigs were premedicated with intramuscular injections
of 20 mg/kg ketamine (Pfizer AS, Norway), 1 mg/kg
midazolam (B. Braun, Germany) and 1 mg atropine
(Nycomed Pharma, Norway). Anesthesia was induced by
inhalation of isoflurane (Abbot, USA). After endotracheal
intubation, intravenous injections of 10 mg/kg pentobar-
bital sodium (Abbott, USA), and 0.01 mg/kg fentanyl
(Hameln Pharmaceuticals, Germany) were administered.
The animals were ventilated on positive-pressure ventila-
tion at 60% oxygen. An introducer sheath catheter was
placed into the left internal jugular vein, and anesthesia
was maintained throughout the experiment by continuous
infusion of 4 mg/kg per h pentobarbital sodium, 0.02 mg/
kg per h fentanyl, and 0.3 mg/kg per h midazolam. The
circulating volume was maintained by 20 mL/kg per h
continuous infusion of 0.9% NaCl supplemented with
1.25 g/L glucose. In addition, the animals received
2500 IU heparin (Leo, Denmark) and 5 mg/kg amio-
darone (Sanofi-Synthelabo, Sweden) to prevent blood
clotting of catheters and cardiac arrhythmia, respec-
tively. The urinary bladder was catheterized and drained
by cystotomy. To enable analysis of the hemodynamic
effects with minimal influence of the sympathetic nervous
system, hexamethonium chloride (Sigma Chemical Co.,
USA) was administered as an intravenous bolus of
20 mg/kg.
A 7 Fr multisegment Millar MPVS Ultra pressure-
volume catheter (Millar, USA) was placed into the left
ventricle via the common carotid artery. Arterial pressure
was measured via a vascular catheter in the abdominal
aorta. A 7 Fr balloon catheter (Sorin, Italy) was intro-
duced into the inferior vena cava for preload reduction.
After median sternotomy, the pericardium was removed,
and the pulmonary truncus was dissected to enable the
placement of a transit time flow probe (Medistim, Nor-
way) for CO measurements. Three sonomicrometry crys-
tals (Sonometrics Corporation, Canada) were placed in
the myocardium to measure the long- and short-axis
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myocardial dimensions. A 6 Fr introducer (Terumo, Bel-
gium) was inserted through the thoracic wall into the left
atrium, through which a 3.5 Fr pressure catheter (Millar,
USA) was placed. A pacemaker electrode was sutured
onto the right atrium. Epicardial echocardiography (Vivid
I, GE, USA) was used to calibrate the crystal dimensions
to the LV volumes at baseline.
Experimental protocol
A full data set was obtained at three time points during
the experiments: (1) pre-ischemia, (2) ischemia, and (3)
postischemic treatment. Data were obtained at intrinsic
HR and during pacing-induced tachycardia. The pacing
protocol was performed in successive steps at 120 and
160 bpm, with at least 1 min between each step to allow
for pressure stabilization. Measurements were performed
at steady state and during an abrupt reduction in preload
induced by vena cava occlusion (VCO) at each time
point. Ventilation was halted in expiration during the
recordings to minimize the effects of respirator-induced
alterations.
Following baseline recordings, LV ischemia was
induced by repeated, fluoroscopic-guided injections of
2–5 mL boluses of 50-lm polystyrene microspheres
(2.4 mg/mL) (NEM-005; NEN Life Science Products,
USA) into the left main coronary artery. The injections
were repeated until the left atrial pressure (LAP)
approached 20 mmHg. An average of 11.9  3.9 mL
was administered over 53  15 min to achieve this level
of heart failure. The ischemic recordings were per-
formed at 30 min after the last coronary injection. The
animals were then split into two groups to receive
either OM or D+I.
OM (Selleck Chemicals, USA) was formulated as a
1 mg/mL solution containing 50 mmol/L citrate in sterile
water, and the pH was adjusted to 5.0 with NaOH
(Bakkehaug et al. 2015). Based on a previously published
dose–response protocol (Bakkehaug et al. 2015), a bolus
dose of 0.75 mg/kg was administered over 10 min, fol-
lowed by a continuous infusion of 0.5 mg/kg per h. This
resulted in a targeted 20% increase in the SET, corre-
sponding to a clinically relevant plasma concentration of
500–1000 ng/mL (Teerlink et al. 2011).
Dobutamine was infused at a dose of 5 lg/kg per min
supplemented with small boluses of ivabradine to attenuate
the chronotropic effect. Five milligrams of ivabradine was
administered via a slow intravenous bolus at 5-min inter-
vals until the target HR (postischemic HR) was achieved or
until the overall dose of ivabradine reached 0.5 mg/kg (av-
erage dose 0.29  0.16 mg/kg) (Vaillant et al. 2008). The
final recordings were performed after a 30-min stabilization
period.
Data analysis
LV pressure, transit time blood flow, sonomicrometric
dimensions and vascular pressure signals were recorded,
digitized, and analyzed using ADI LabChart Pro software
(AD Instruments, New Zealand). Cardiac dimensions
were measured at baseline and after the interventions
from the short- and long-axis sonomicrometry crystals,
and the measurements were corrected by the epicardial
short-axis ultrasound data at baseline. The echocardio-
graphic endocardial long axis (Lendo) was calculated from
the endocardial short axis (Sendo) at a ratio of 1.37 (Ros-
ner et al. 2009). The sonomicrometric signals were con-
verted to LV end-diastolic volume (EDV) and LV ESV
using the ellipsoid formula V=p(Sendo)
2/6*Lendo (Zile
et al. 1992). EF was calculated using the formula [EDV –
ESV]/EDV * 100%. A transit time flow probe on the
pulmonary artery provided CO measurements. SV was
calculated from the flow probe data by CO/HR. SET was
defined as the time between dP/dtmax and dP/dtmin, and
diastolic time (DT) was defined as the remaining fraction
of the cardiac cycle. The isovolumetric relaxation constant
(Tau) was calculated by Weiss’ method. To obtain the
preload recruitable stroke work (PRSW), we performed
transient VCO at spontaneous HR, whereas the end-dia-
stolic and end-systolic pressure–volume relationships
(EDPVR and ESPVR, respectively) were calculated as the
linear slopes of the steady state measurements. The maxi-
mum atrial-ventricular gradient (L A-V MAX) is the peak
pressure difference between the left atrium and left ventri-
cle during diastole, and the atrial-ventricular pressure–
time integral (L A-V INTG) is the area under the curve
during diastole. The maximum myocardial systolic defor-
mation rate (s0) was measured as the peak negative
derivative of the long-axis sonomicrometry crystal,
whereas e0 was measured as the peak positive derivative
during diastole.
Statistics
Values are presented as the mean and standard deviation.
To assess the impact of microembolization and treatment
at intrinsic heart rate, the data were analyzed using paired
Student’s t test. To assess the effects of pacing induced
tachycardia on treatment, the data were analyzed by two-
way mixed design ANOVA. P values <0.05 were regarded
as statistically significant, and all analyses were conducted
using SPSS version 23 (SPSS Inc., USA).
Results
Global LV ischemia impaired early (Tau, Pmin, and dP/
dtmin) and late diastole (end-diastolic pressure, EDP),
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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resulting in diastolic dysfunction. Interestingly, both the L
A-V MAX and L A-V INTG were maintained despite impaired
early relaxation of the ischemic heart. Despite a twofold
increase in the LV preload, the impaired systolic and dias-
tolic function led to reductions in the SV, cardiac output,
and mean arterial pressure.
Both treatments (OM and D+I) improved systolic
unloading of the ischemic ventricle. The two treatments
differed in three principal aspects: (1) the speed of con-
traction; (2) the speed of relaxation; and (3) the rela-
tionship between the systolic and diastolic times during
the cardiac cycle. D+I reversed the ischemia-induced
impairments in inotropy and lusitropy, as demonstrated
by a 77% increase in dP/dtmax, an 89% increase in dP/
dtmin, and a 35% decrease in Tau (Table 1). Conversely,
OM had no impact on dP/dt, and it prolonged Tau by
50%. In addition, D+I reduced the minimum LV pres-
sure (Pmin) and thus increased the L A-V MAX during
diastole. However, OM had no impact on these indices.
OM biased the cardiac cycle towards systole, while D+I
biased it towards diastole. The enhanced early relaxation
and prolongation of diastole by D+I resulted in an
increased L A-V INTG beyond the pre-ischemia levels.
This was associated by increases in the SV (27%), mean
arterial pressure (18%) and ejection fraction (from 24%
to 32%). In contrast, the reduction in the DT and the
impaired relaxation (Tau) observed with OM adminis-
tration resulted in a leftward shift of the pressure–vol-
ume loop (Fig. 5). Thus, OM failed to restore general
pump indices, such as the SV, CO, mean arterial pres-
sure, and ejection fraction. At elevated heart rate by
atrial pacing the opposite effects of OM versus D+I
treatment was reinforced (Figs. 1–3).
Discussion
Main findings
This study shows that catecholamine-induced inotropy
(D+I) and direct myosin activation (OM) had opposite
effects on diastolic function in the ischemic heart.
Improved diastole by D+I was attributed to enhanced
early relaxation and a prolonged DT that increased the
driving force across the mitral valve. In contrast, OM
unloaded the heart by prolonging systole at the expense
of the DT. Together with impaired early relaxation, this
reduced the driving force across the mitral valve. These
diastolic impairments with OM were indicated by the left-
ward shift of the pressure–volume loop (Fig. 5) and


























































































































Figure 1. General hemodynamics at intrinsic heart rates and during right atrial pacing at 120 and 160 beats/min. The left panels show the
pre-ischemia (white bars; n = 12) and ischemia values (black bars; n = 12). The right panels show the effects of the inotropic treatments as
delta changes from the ischemia values. The blue bars indicate the omecamtiv mecarbil (OM) treatment group (n = 6), and the yellow bars
indicate the dobutamine plus ivabradine (D+I) treatment group (n = 6). *P < 0.05 pre- versus post-ischemia (paired t test). †P < 0.05 ischemia
versus treatment groups (two-way mixed ANOVA). ‡P < 0.05 between treatment groups (two-way mixed ANOVA).
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Restoring compromised SV is thought to be an impor-
tant treatment target in postischemic CS. Data from the
SHOCK trial (Hochman et al. 1999) indicated that stroke
work and SV, which are indicators of pump function, are
superior early predictors of patient survival (Jeger et al.
2007). Thus, the rationale for inotropic support as a
short-term bridge to recovery in the sickest patients may
be justified despite the lack of improved outcomes in
clinical trials (Ponikowski et al. 2016). Inotropes increase
SV primarily by enhancing systolic unloading. The
restoration of systolic function is critical because CS
patients often exhibit dilated ventricles due to severely
compromised contractility (Hochman et al. 1999). How-
ever, little attention has been paid to diastolic function in
these patients. Using Doppler echocardiography, a sub-
study of the SHOCK trial revealed that 60.9% of the
patients presented with a restrictive filling pattern (Rey-
nolds et al. 2006), which was associated with a more sev-
ere form of shock. These patients exhibited a trend
toward increased mortality, indicating that diastolic dys-
function contributed to the pathology in these patients.
Other studies have also reported that patients with
diastolic pathology exhibit increased risks of morbidity
and mortality following acute myocardial infarction (Mol-
ler et al. 2006).
Impact of acute ischemia on diastolic
function
Acute ischemia is known to induce diastolic dysfunction
(Labovitz et al. 1987), as demonstrated by impaired and/
or incomplete early relaxation or acute stiffening of the
ventricle, leading to late diastolic constraint (Miyazaki
et al. 1990). At the myocyte level, impaired early relax-
ation is related to incomplete or delayed calcium reuptake
at the sarcomere, contributing to resting tension during
relaxation (Westerblad and Allen 1993). Additionally,
early diastolic function is dependent on restoring forces
in the myocardium, which are generated by elastic recoil
as the ventricle expands to regain its passive shape in
early diastole (Opdahl et al. 2009). During acute ische-
mia, such diastolic suction is absent, as systolic unloading
is incomplete (Courtois et al. 1990). Our study has con-
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Figure 2. Systolic indices at intrinsic heart rates and during right atrial pacing at 120 and 160 beats/min. The left panels show the pre-
ischemia (white bars; n = 12) and ischemia values (black bars; n = 12). The right panels show the effects of the inotropic treatments as delta
changes from the ischemia values. The blue bars indicate the omecamtiv mecarbil (OM) treatment group (n = 6), and the yellow bars indicate
the dobutamine plus ivabradine (D+I) treatment group (n = 6). ESV, end-systolic volume; ESP, end-systolic pressure; SET, systolic ejection time;
ESPVR, slope of steady state end-systolic pressure–volume relationship; s0, peak LV long-axis wall deformation velocity; and dP/dtmax, maximum
rate of LV pressure change. *P < 0.05 pre- versus post-ischemia (paired t test). †P < 0.05 ischemia versus treatment groups (two-way mixed
ANOVA). ‡P < 0.05 between treatment groups (two-way mixed ANOVA).
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by the substantial increase in the isovolumetric relaxation
time, reduction in the maximum speed of relaxation and
elevation in the minimum ventricular pressure during the
cardiac cycle. These effects can be at least partly attributed
to a lack of diastolic suction because ischemia also sub-
stantially impairs systolic unloading. Interestingly, despite
the impaired relaxation rate of the LV, the peak atrial-
ventricular pressure differences were maintained in
ischemia. This finding is most likely due to the twofold
increase in the LAP, causing the first LAP-LVP crossover
at an earlier and steeper part of the LVP curve (see
Fig. 4).
The impact of acute ischemia on ventricular distensibil-
ity in mid to late diastole appears to be multifactorial
(Miyazaki et al. 1990). The underlying causes of acute
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Figure 3. Diastolic indices at intrinsic heart rates and during right atrial pacing at 120 and 160 beats/min. The left panels show the pre-ischemia
(white bars) and ischemia values (black bars) (n = 12). The right panels show the effects of the inotropic treatments as delta changes from the
ischemia values. The blue bars indicate the omecamtiv mecarbil (OM) treatment group (n = 6), and the yellow bars indicate the dobutamine plus
ivabradine (D+I) treatment group (n = 6). EDV, end-diastolic volume; EDP, end-diastolic pressure; EDPVR, slope of steady state end-diastolic
pressure–volume relationship; e0, peak LV long-axis elongation velocity; L A-V MAX, peak L atrial-ventricular pressure difference; L A-V INTG,
L atrial-ventricular pressure–time integral during diastole; Tau, isovolumetric relaxation constant; Pmin, minimum LVP; dP/dtmin, maximum rate of
pressure decline; SV/L A-V INTG, SV related to the L atrial-ventricular pressure–time integral. *P < 0.05 pre- versus post-ischemia (paired t test).
†P < 0.05 ischemia versus treatment groups (two-way mixed ANOVA). ‡P < 0.05 between treatment groups (two-way mixed ANOVA).
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overload (Steenbergen et al. 1987) and/or myocardial
edema (Schulz-Menger 2011). Late diastolic dysfunction
was also observed in our model, as demonstrated by the
substantial elevation in the EDPVR. Additionally, we
assessed distensibility using a novel method. By relating
the atrial-ventricular driving force (measured as the time–
pressure integral of left atrium-ventricle during diastole)




























































































Figure 4. Modified Wiggers’ diagram showing examples of actual tracings from two pigs. Left column: pre-ischemia, ischemia, and
dobutamine-ivabradine (D+I) treatment. Right column: pre-ischemia, ischemia, and omecamtiv mecarbil (OM) treatment. LVP, left ventricular
pressure; LAP, left atrial pressure; dP/dtmax and dP/dtmin, maximum and minimum derivatives of the LV pressure, respectively; Tau, isovolumetric
relaxation constant; Pmin, minimum LV pressure during the cardiac cycle; L A-V MAX, peak L atrial-ventricular pressure difference; L A-V INTG,
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Figure 5. Illustration of typical pressure–volume loops at intrinsic heart rates calibrated against the mean values of ESV, EDV, EDP, Pmin, and
ESP, as shown in Table 1. The left panel shows pre- (dotted line) and post-ischemia (solid line). The middle panel shows treatment with
dobutamine plus ivabradine (D+I, yellow line) compared with untreated ischemia. The right panel shows treatment with omecamtiv mecarbil
(OM, blue line) compared with untreated ischemia.
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we observed a substantial constraint against diastolic fill-
ing in the ischemic heart (Fig. 3). These findings are in
line with the restrictive filling patterns often observed in
severely ill CS patients (Reynolds et al. 2006).
Effects of treatment
Ivabradine has been suggested for use as an adjunct to
dobutamine in the treatment of CS (Gallet et al. 2014) to
counteract undesired tachycardia. This medication does
not affect inotropy, and treatment with D+I have been
suggested to optimize coronary flow and reduce energy
demands in the ischemic heart by optimizing the DT (De
Santis et al. 2013; Gallet et al. 2014). The results obtained
in the present study are in agreement with these previous
findings showing that treatment with D+I increase the
DT. The animals receiving either OM or D+I exhibited
enhanced systolic unloading in the ischemic dilated ven-
tricle. Therefore, both treatments should enhance restor-
ing forces, which would facilitate suction in early diastole
(Opdahl et al. 2009). However, only the pigs receiving
D+I exhibited improvements in early diastolic indices
(Fig. 3). In fact, with the exception of systolic unloading,
the effects of the two treatments were quite opposite. This
dichotomy is most likely due to the distinct effects of the
drugs on the sarcomere. Catecholamines act on b-adre-
nergic receptors to enhance transient cytosolic Ca2+
amplitude (inotropy) and increase the rate of sarcoplas-
mic reticulum Ca2+ reuptake (lusitropy) (Bers 2002). The
intracellular ion fluxes can be mirrored in the whole heart
by measuring dP/dtmin and dP/dtmax. These findings were
confirmed in our study, which showed that ischemia
reduced the speed of LVP acceleration and deceleration,
which was restored by administration of the b-agonist
dobutamine in combination with ivabradine. However,
pro-arrhythmogenic effects and a potentially increased
energetic cost (Muller et al. 2010) are associated with the
use of sympathomimetic drugs. These disadvantages have
prompted the research and development of alternative
inotropes, such as calcium sensitizers and myosin activa-
tors, that do not alter intracellular calcium levels. The
sensitizer levosimendan has reached clinical application,
but studies have indicated that its inotropic effects may
be attributed to PDE3 inhibition (Ørstavik et al. 2014).
At present, the myosin activator OM has not been
demonstrated to modulate calcium (Malik and Morgan
2011), which is in line with the unaltered dP/dtmax
observed in the OM-treated animals in this study.
Instead, OM treatment improves systolic unloading by
prolonging the SET (Malik and Morgan 2011). In car-
diomyocytes, this is evident as an abnormal inotropic
response with a negative treppe (force–frequency relation-
ship) and offset in the relationship between intracellular
calcium amplitude and sarcomere shortening (Butler et al.
2015). Our data indicate that the diastolic consequence of
this mechanism of action is prolonged and slowed relax-
ation. This is in line with the previous finding that OM
slows relaxation and increases passive tension at rest in
isolated cardiomyocytes (Nagy et al. 2015). In intact sub-
jects, these effects are reflected by an increased Tau and
reduced dP/dtmin. In addition, the consequence of an
increased SET is a reduced DT. These findings highlight
underlying mechanisms that could explain why OM fails
to restore the SV in ischemic hearts. And indeed, when
DT was further shortened by tachycardia, OM treatment
caused a general hemodynamic decompensation (Fig. 1).
The constrain with OM treatment is also displayed by
that improvements in systolic unloading are counteracted
by impairments in diastolic filling, as demonstrated by
the leftward shift of the entire pressure–volume loop
(Fig. 5).
Conclusion
Our data demonstrated that controlling tachycardia with
ivabradine optimizes the lusitropic effect of dobutamine
in ischemic acute heart failure. In contrast, inotropic sup-
port with omecamtiv mecarbil is limited by the impair-
ment in diastolic function that is reinforced at elevated
heart rates.
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